SWOG S1801: A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma

Objective

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better compared to after surgery alone in treating melanoma.

https://clinicaltrials.gov/ct2/show/NCT03698019

Location: Essentia Health Cancer Centers

Research Study Categories

  • Adult Studies

Specialty

  • Skin Cancer
Contact
Cancer Clinical Trials at 218-786-3308
or cancertrials@essentiahelath.org

Like most websites, we use cookies and other technologies to keep our website reliable, secure, and to better understand how our site is used. By using our site, you agree to our use of these tools. Learn more.